📊 LXRX Key Takeaways
Is LXRX a Good Investment? Thesis Analysis
Lexicon Pharmaceuticals exhibits severe operational distress with negative operating margins exceeding -98% and operating cash burn of $67.9M, indicating the company is consuming substantially more cash than it generates. Despite 60% revenue growth, the company is unprofitable at all levels and burning through cash reserves, with only $34.3M in cash against $49.4M in long-term debt, creating near-term solvency concerns.
Why Buy LXRX? Key Strengths
- Strong liquidity position with 4.88x current ratio providing short-term flexibility
- Significant revenue growth of 60.2% YoY demonstrates market traction for products
- Moderate leverage with 0.46x debt-to-equity ratio indicates not over-leveraged relative to equity base
LXRX Investment Risks to Consider
- Severe cash burn of $67.9M annually with only 6-9 months of cash runway at current burn rate
- Operating losses of $48.9M on $49.8M revenue indicates business model fundamentally unprofitable at scale
- Negative operating cash flow and -136.2% FCF margin indicate growth is destroying rather than creating shareholder value
- Long-term debt of $49.4M approaching total cash reserves creates refinancing risk if operations don't improve
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Quarterly revenue growth sustainability and gross margin expansion as volumes scale
- Monthly cash burn rate and cash runway remaining before potential capital raise or debt covenant issues
LXRX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.88x current ratio provides a solid financial cushion.
LXRX Profitability Ratios
LXRX vs Healthcare Sector
How LEXICON PHARMACEUTICALS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LXRX Overvalued or Undervalued?
Based on fundamental analysis, LEXICON PHARMACEUTICALS, INC. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LXRX Balance Sheet & Liquidity
LXRX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LEXICON PHARMACEUTICALS, INC.'s revenue has declined by 77% over the 5-year period, indicating business contraction. The most recent EPS of $-0.80 indicates the company is currently unprofitable.
LXRX Growth Metrics (YoY)
LXRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $1.1M | -$25.3M | $-0.07 |
| Q3 2024 | $148.0K | -$31.9M | $-0.18 |
| Q2 2024 | $291.0K | -$31.9M | $-0.17 |
| Q1 2024 | N/A | -$31.9M | $-0.17 |
| Q3 2023 | N/A | -$23.4M | $-0.13 |
| Q2 2023 | N/A | -$23.5M | N/A |
| Q3 2021 | N/A | -$18.1M | $-0.16 |
| Q2 2021 | N/A | -$18.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LXRX Capital Allocation
LXRX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LEXICON PHARMACEUTICALS, INC. (CIK: 0001062822)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LXRX
What is the AI rating for LXRX?
LEXICON PHARMACEUTICALS, INC. (LXRX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LXRX's key strengths?
Claude: Strong liquidity position with 4.88x current ratio providing short-term flexibility. Significant revenue growth of 60.2% YoY demonstrates market traction for products.
What are the risks of investing in LXRX?
Claude: Severe cash burn of $67.9M annually with only 6-9 months of cash runway at current burn rate. Operating losses of $48.9M on $49.8M revenue indicates business model fundamentally unprofitable at scale.
What is LXRX's revenue and growth?
LEXICON PHARMACEUTICALS, INC. reported revenue of $49.8M.
Does LXRX pay dividends?
LEXICON PHARMACEUTICALS, INC. does not currently pay dividends.
Where can I find LXRX SEC filings?
Official SEC filings for LEXICON PHARMACEUTICALS, INC. (CIK: 0001062822) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LXRX's EPS?
LEXICON PHARMACEUTICALS, INC. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LXRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LEXICON PHARMACEUTICALS, INC. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LXRX stock overvalued or undervalued?
Valuation metrics for LXRX: ROE of -46.8% (sector avg: 15%), net margin of -101.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LXRX stock in 2026?
Our dual AI analysis gives LEXICON PHARMACEUTICALS, INC. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LXRX's free cash flow?
LEXICON PHARMACEUTICALS, INC.'s operating cash flow is $-67.9M, with capital expenditures of $0.0. FCF margin is -136.2%.
How does LXRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -101.1% (avg: 12%), ROE -46.8% (avg: 15%), current ratio 4.88 (avg: 2).